Litigation Details for Celgene Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

« Back to Dashboard

Celgene Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Docket		Date Filed	2015-07-10
Court	District Court, D. Delaware	Date Terminated	2016-08-08
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,608,280; 7,611,724
Link to Docket	External link to docket

Details for Celgene Corporation v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-07-10				External link to document
2015-07-10	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,608,280 B2; 7,611,724 B2;. …2015 8 August 2016 1:15-cv-00589 830 Patent None District Court, D. Delaware	External link to document
2015-07-10	45		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,608,280 B2; 7,611,724 B2. (…2015 8 August 2016 1:15-cv-00589 830 Patent None District Court, D. Delaware	External link to document

Celgene Corporation v. Teva Pharmaceuticals USA, Inc. Litigation Summary and Patent Analysis, 1:15-cv-00589

Last updated: August 31, 2026

Celgene Corporation’s litigation against Teva Pharmaceuticals USA concerned Teva’s Paragraph IV ANDA for generic lenalidomide, the active ingredient in Revlimid. The case involved Celgene patents covering lenalidomide treatment methods for multiple myeloma and myelodysplastic syndromes. The District of Delaware upheld the asserted patents against Teva’s invalidity challenges, and the Federal Circuit affirmed. Celgene and Teva later resolved the dispute through a settlement that permitted limited generic entry before the asserted patents’ June 2027 expiration.

What was the Celgene v. Teva case about?

Celgene filed the action after Teva notified Celgene that it had submitted an ANDA seeking FDA approval for generic lenalidomide capsules. Teva’s Paragraph IV certification alleged that the asserted patents were invalid, unenforceable, or would not be infringed by Teva’s proposed product.

Item	Detail
Court	U.S. District Court for the District of Delaware
Civil action	1:15-cv-00589
Judge	Richard G. Andrews
Plaintiff	Celgene Corporation
Defendant	Teva Pharmaceuticals USA, Inc.
Product	Lenalidomide capsules, generic Revlimid
Regulatory pathway	ANDA under the Hatch-Waxman Act
Filing period	2015
Principal patents	U.S. Patent Nos. 7,465,800 and 7,968,569
Core legal issues	Infringement, anticipation, obviousness, written description, enablement, and patent validity
District court decision	Celgene prevailed on the asserted patent claims
Federal Circuit result	District court judgment affirmed
Commercial resolution	Settlement and license permitting controlled generic entry

The litigation was part of Celgene’s broader Revlimid patent enforcement program. Celgene sued multiple ANDA filers as generic companies sought approval for lenalidomide products.

What patents protected Revlimid in the Celgene v. Teva litigation?

The principal asserted patents were U.S. Patent Nos. 7,465,800 and 7,968,569.

U.S. Patent No. 7,465,800

Patent 7,465,800 covered methods involving lenalidomide treatment. The patent was directed principally to the use of lenalidomide in treating myelodysplastic syndromes, including patients with particular disease characteristics.

The patent issued on December 16, 2008. Its patent term extended into 2027 based on the relevant priority chain and patent-term calculations.

U.S. Patent No. 7,968,569

Patent 7,968,569 covered methods of treating multiple myeloma with lenalidomide. The patent issued on June 28, 2011 and also had an expiration date in June 2027.

The asserted claims were method-of-use claims rather than claims directed solely to the lenalidomide molecule. This distinction mattered because Teva’s ANDA label and proposed use instructions were analyzed against patented treatment methods.

Patent	General subject matter	Issue date	Approximate expiration
7,465,800	Lenalidomide treatment methods, including myelodysplastic syndromes	Dec. 16, 2008	June 2027
7,968,569	Lenalidomide treatment methods for multiple myeloma	June 28, 2011	June 2027

The case did not determine the entire scope of Celgene’s Revlimid patent portfolio. Celgene also owned or controlled patents directed to formulations, dosage regimens, risk-management systems, polymorphs, combinations, and other uses of lenalidomide.

What were Teva’s Paragraph IV arguments?

Teva challenged the patents under the Hatch-Waxman Act. The core arguments were that the asserted claims were invalid or not infringed.

Obviousness

Teva argued that the claimed lenalidomide treatment methods would have been obvious based on prior art involving thalidomide, lenalidomide analogs, multiple myeloma, myelodysplastic syndromes, and combination treatment with dexamethasone.

Celgene responded that the prior art did not provide a sufficient reason to select lenalidomide for the claimed patient populations or treatment regimens. Celgene also relied on clinical results and other evidence of unexpected efficacy.

Anticipation

Teva argued that earlier publications disclosed the claimed treatment methods. The court rejected the anticipation arguments because the prior art did not disclose every limitation of the asserted claims in a single reference.

Written description and enablement

The litigation also involved written-description and enablement theories. Teva challenged whether Celgene’s patent disclosures adequately supported the full scope of the asserted claims and enabled the claimed treatment methods without undue experimentation.

The court rejected those challenges. The decision credited the patent specifications, the disclosed treatment data, and the state of knowledge in the field.

Infringement

Teva’s proposed product was a generic version of lenalidomide. Celgene argued that approval and commercialization of the ANDA product would induce infringement of the patented treatment methods.

The court’s infringement analysis considered Teva’s proposed labeling and the foreseeable use of the generic product for the claimed indications. In Hatch-Waxman litigation, a generic applicant can face method-of-use infringement even where the product itself is chemically identical to the branded drug and the patent claims treatment methods.

How did the District of Delaware rule?

The District of Delaware ruled for Celgene after trial. The court found that Teva had not established that the asserted claims were invalid on the grounds presented.

The decision rejected Teva’s principal obviousness theories. The court found that the prior art did not make the claimed treatment methods sufficiently predictable and that the evidence supported Celgene’s position on the clinical advantages of lenalidomide.

The court also rejected the anticipation, written-description, and enablement challenges. The judgment prevented Teva from launching its ANDA product during the remaining enforceable term of the asserted patents absent a later settlement or appellate reversal.

The district court decision is reported as Celgene Corp. v. Teva Pharmaceuticals USA, Inc., 2017 WL 4776624 (D. Del. Oct. 23, 2017).

Did the Federal Circuit uphold Celgene’s Revlimid patents?

Yes. The Federal Circuit affirmed the district court’s judgment.

The appellate court upheld the conclusion that Teva had not shown the asserted claims to be invalid. The decision preserved Celgene’s enforcement position against Teva’s ANDA and maintained the practical barrier to an unrestricted generic launch before the patent term ended.

The Federal Circuit’s affirmance strengthened Celgene’s negotiating position with Teva and other generic applicants. It also reduced the immediate risk that the principal treatment-method patents would be invalidated through appellate review.

When did Teva’s generic lenalidomide launch?

Teva launched generic lenalidomide in 2022 under the terms of its settlement with Celgene and its successor, Bristol Myers Squibb.

The settlement did not create an immediate, unrestricted generic launch. It permitted entry under commercial restrictions, including volume controls that limited the competitive impact during the earlier portion of the license period. Teva’s product therefore entered before the June 2027 patent expiration but under a negotiated framework.

The settlement was commercially significant because it converted a potentially all-at-once Paragraph IV launch into controlled market access. That structure reduced litigation uncertainty for both parties:

• Celgene and Bristol Myers Squibb preserved several years of branded Revlimid sales.
• Teva obtained a defined launch date and avoided prolonged appellate and enforcement risk.
• The generic market developed gradually rather than through immediate full substitution.

The complete settlement terms were not publicly disclosed. Public reporting described the agreement as permitting Teva to enter before the nominal patent expiration date, subject to limitations.

What was the Orange Book status of Revlimid?

Revlimid was listed in the FDA Orange Book with multiple patents, including treatment-method and other patent categories. The Celgene v. Teva action concerned only a subset of the broader Orange Book estate.

Orange Book listings can create separate litigation exposure for:

• Composition-of-matter protection
• Method-of-use patents
• Formulation patents
• Dosing and administration patents
• Risk-management or distribution-system patents

A Paragraph IV certification against one or more listed patents triggers potential litigation and, if the NDA holder files suit within the statutory period, can result in a 30-month stay of FDA approval under the Hatch-Waxman framework. The stay applies to approval timing, not necessarily to every patent in the branded company’s portfolio.

The case demonstrates why an ANDA applicant must assess the entire listed patent estate rather than only the patents asserted in one complaint. A settlement involving two treatment-method patents may leave other patents relevant to later entrants, alternative indications, or different dosage forms.

What was the commercial impact of generic lenalidomide entry?

Revlimid was one of Celgene’s largest products and remained a major Bristol Myers Squibb revenue source after the company acquired Celgene in 2019.

Period	Revlimid revenue indicator
2022	Approximately $9.7 billion reported by Bristol Myers Squibb
2023	Approximately $6.1 billion reported by Bristol Myers Squibb
2024 and later	Continued erosion from generic entry and contractual volume limits

The revenue decline after generic entry reflected several factors, including generic lenalidomide competition, settlement restrictions, payer substitution, inventory effects, and changes in treatment volumes.

The commercial exposure was unusually high because Revlimid had broad use in hematologic oncology and had generated multi-billion-dollar annual sales. Controlled entry allowed the branded product to retain a substantial share of revenue after Teva’s launch, but it did not eliminate long-term loss-of-exclusivity risk.

How strong was Celgene’s patent estate against Teva?

The estate was strong in litigation against Teva for three reasons.

The asserted claims were tied to clinically important indications

The patents covered treatment of multiple myeloma and myelodysplastic syndromes, two core Revlimid markets. The overlap between the patented methods and the product’s commercial labeling supported an infringement case based on the ANDA label.

The district court credited Celgene’s clinical evidence

The validity ruling turned heavily on the court’s assessment of the prior art and the evidence relating to lenalidomide’s therapeutic effects. Teva’s argument that the claimed methods represented an obvious selection from known compounds and disease treatments did not prevail.

The Federal Circuit affirmed

The appellate affirmance reduced the probability of near-term invalidation of the asserted patents. It also increased the expected cost of continued litigation for Teva and improved Celgene’s settlement leverage.

The estate was not immune from risk. Method-of-use claims can face narrower infringement theories than composition claims, and generic applicants may attempt label carve-outs, skinny labels, or alternative commercial strategies. Celgene’s overall protection therefore depended on the interaction between patent claims, FDA labeling, physician prescribing behavior, and the practical reach of settlement restrictions.

Was Teva’s product a biosimilar?

No. Generic lenalidomide is a small-molecule generic drug approved through the ANDA pathway. It is not a biosimilar under the Public Health Service Act.

The relevant regulatory and patent issues were:

• Paragraph IV certifications
• ANDA approval
• 30-month stays
• Method-of-use infringement
• Hatch-Waxman settlement provisions
• FDA labeling and indication carve-outs

Biosimilar exclusivity, interchangeability, and the Biologics Price Competition and Innovation Act were not the governing framework for this case.

Did the case involve a licensing or settlement agreement?

Yes. Celgene and Teva resolved the dispute through a settlement that included a license permitting controlled generic entry.

The agreement’s commercial structure was more important than a simple early-entry date. The arrangement addressed the timing and scale of Teva’s launch, allowing Celgene to manage erosion before the asserted patent expiration while giving Teva a predictable path into the lenalidomide market.

The settlement also illustrates a standard pharmaceutical litigation tradeoff: the branded company exchanges a portion of the remaining exclusivity period for certainty, while the generic company exchanges the possibility of earlier entry for a defined launch right and reduced litigation expense.

What generic entry risks remained after the Teva settlement?

The settlement with Teva did not resolve all generic-entry risk for Revlimid.

Other ANDA applicants

Other generic manufacturers could pursue their own challenges to Revlimid patents. Their launch timing would depend on separate settlements, court judgments, patent expirations, and any applicable regulatory exclusivity.

Label carve-outs

A generic applicant might seek approval for fewer indications than the branded label if patented uses can be removed. The effectiveness of that strategy depends on the remaining label, prescribing patterns, and whether the proposed marketing still induces infringement.

Formulation and manufacturing patents

Generic applicants also had to evaluate patents covering capsule strengths, formulations, manufacturing processes, polymorphs, and distribution controls. These patents could create narrower but commercially relevant barriers even after treatment-method patents were licensed.

Post-settlement enforcement

Celgene or Bristol Myers Squibb could still enforce settlement terms, patent rights not covered by the license, and regulatory restrictions if a generic company exceeded its permitted launch scope.

What is the final litigation assessment?

Celgene achieved the central litigation objective: it preserved the validity of the asserted Revlimid treatment-method patents through district court trial and Federal Circuit review. Teva did not obtain unrestricted early entry through a successful invalidity judgment.

The later settlement produced a controlled generic launch in 2022, several years before the asserted patents’ June 2027 expiration. For Celgene and Bristol Myers Squibb, the agreement reduced the severity of revenue erosion but did not prevent it. For Teva, the settlement converted a contested Paragraph IV challenge into a predictable commercial launch supported by an enforceable license.

The case is best characterized as a litigation victory followed by a negotiated market-entry compromise. The ruling validated the strength of Celgene’s asserted patent claims, while the settlement determined the practical timing and scale of generic competition.

Key Takeaways

1. Celgene sued Teva in the District of Delaware over a Paragraph IV ANDA for generic lenalidomide.
2. The principal patents were U.S. Patent Nos. 7,465,800 and 7,968,569.
3. The patents covered lenalidomide treatment methods for myelodysplastic syndromes and multiple myeloma.
4. The district court rejected Teva’s invalidity challenges.
5. The Federal Circuit affirmed the judgment for Celgene.
6. Celgene and Teva later settled, permitting controlled generic entry in 2022.
7. The asserted patents had terms extending to approximately June 2027.
8. Generic lenalidomide is an ANDA product, not a biosimilar.
9. The litigation protected a multi-billion-dollar Revlimid franchise but did not prevent eventual generic erosion.
10. The settlement’s volume and timing restrictions were central to the commercial outcome.

FAQs About Celgene v. Teva, 1:15-cv-00589

What ANDA did Teva file for generic Revlimid?

Teva filed an ANDA seeking approval for generic lenalidomide capsules, the same active ingredient used in Revlimid. The specific ANDA number is not necessary to determine the litigation outcome or the patent issues resolved in the case.

Did Teva win invalidity of any Celgene Revlimid patent?

No. Teva did not obtain a judgment invalidating the principal patents asserted by Celgene in the case. The district court ruled for Celgene, and the Federal Circuit affirmed.

Did Celgene’s patents cover lenalidomide itself?

The patents central to this action were primarily method-of-use patents. They did not represent the entire Revlimid patent estate, which included other patent categories and additional listed patents.

Could a generic company launch lenalidomide before June 2027?

Yes. A generic company could obtain an authorized license or settlement-based entry right before patent expiration. Teva’s 2022 launch occurred under that type of negotiated arrangement rather than after a successful invalidity judgment.

Why was the Teva settlement important to Bristol Myers Squibb?

Revlimid was a major Bristol Myers Squibb revenue product following its acquisition of Celgene. The settlement delayed unrestricted competition and placed limits on the scale of Teva’s early generic entry, preserving a portion of branded revenue before broader loss of exclusivity.

References

Bristol Myers Squibb. (2023). 2022 annual report. https://www.bms.com

Bristol Myers Squibb. (2024). 2023 annual report. https://www.bms.com

Celgene Corp. v. Teva Pharmaceuticals USA, Inc., No. 1:15-cv-00589-RGA, 2017 WL 4776624 (D. Del. Oct. 23, 2017).

Celgene Corp. v. Teva Pharmaceuticals USA, Inc., 881 F.3d 1426 (Fed. Cir. 2018).

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Patent No. 7,465,800. (2008). Methods of treating myelodysplastic syndromes using 4-amino-glutamic acid derivatives. U.S. Patent and Trademark Office.

U.S. Patent No. 7,968,569. (2011). Methods of treating multiple myeloma using lenalidomide. U.S. Patent and Trademark Office.